Intuitive Surgical filings document operating results, governance matters, capital structure, and material events for a Nasdaq-listed medical technology company focused on robotic-assisted surgery. Its Form 8-K reports furnish quarterly and preliminary financial results, procedure information, and exhibits tied to da Vinci and Ion business performance.
Regulatory filings also cover shareholder voting matters, proxy governance, executive compensation, director elections, and officer-role changes. Other material-event disclosures record completed corporate actions, including the acquisition of da Vinci and Ion distribution operations in Europe, alongside formal disclosures about common stock and financial reporting matters.
A shareholder has filed a Form 144 indicating an intention to sell up to 2,800 shares of common stock through The Charles Schwab Corporation on the NASDAQ, with an aggregate market value of 1,488,269.00. The filing lists 354,496,073 shares of this class as outstanding, providing context for the planned sale. The shares to be sold were acquired on 12/03/2018 via a stock option exercise from the issuer, with payment made on the same date.
Intuitive Surgical, Inc. filed a current report stating that it issued a press release announcing its financial results for the quarter ended December 31, 2025. The press release is furnished as Exhibit 99.1, giving investors access to the company’s quarterly performance details outside this report.
The company notes that the information contained in the report, including Exhibit 99.1, is being furnished rather than filed, meaning it is not subject to certain liability provisions under the Securities Exchange Act and is not automatically incorporated into other SEC filings. The report is signed on behalf of Intuitive by its Executive Vice President and Chief Financial Officer, Jamie E. Samath.
Intuitive Surgical, Inc. furnished a report stating that it has issued a press release with unaudited preliminary financial results for the fourth quarter and full year 2025. The release is provided as Exhibit 99.1.
The company also supplied additional unaudited preliminary revenue and procedure information in tabular form as Exhibit 99.2, which has been posted to the Investor Relations section of its website. The materials are designated as furnished rather than filed, meaning they are not subject to certain Exchange Act liabilities or automatically incorporated into other securities law filings.
Intuitive Surgical, Inc. reported a leadership role change in its digital organization. Effective January 1, 2026, Brian E. Miller, Ph.D., will move from his current position as Chief Digital Officer to become Head of Digital and AI Strategy. In this new role, Dr. Miller will continue focusing on the company’s digital and artificial intelligence initiatives but will no longer report directly to the Chief Executive Officer. The filing does not describe additional changes to his responsibilities or to other executive roles.
Intuitive Surgical Inc. reported that a senior officer sold company stock. On 12/15/2025, the SVP & Chief Mfg and Supply Chain Officer sold 464 shares of common stock at a price of $548.49 per share in an open market transaction. After this sale, the officer beneficially owned 131 shares, held directly.
The company notes that the trade was executed under a pre-established Rule 10b5-1 trading plan, which is designed to allow insiders to sell shares according to a predetermined schedule. This plan is stated to comply with SEC Rule 10b5-1 and is scheduled to expire on February 14, 2027.
Intuitive Surgical executive Mark Brosius reported an amended insider transaction showing an open-market sale of 312 shares of Common Stock at $547.36 per share on December 12, 2025. After this sale, he directly owned 595 shares.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan that is scheduled to expire on February 14, 2027. This Form 4/A corrects the third transaction line from his Form 4 filed on December 15, 2025, which had incorrectly reported that transaction’s details, while all other information in the original filing remained accurate.
Intuitive Surgical executive Mark Brosius reported stock option exercises and share sales. As SVP & Chief Manufacturing and Supply Chain, he exercised 4,500 non-qualified stock options for common stock at an exercise price of $79.6378 per share on 12/12/2025, then sold 4,500 common shares that day at $547.36 per share.
He also sold 464 common shares on 12/15/2025 at $548.49 per share. After these transactions, he directly owned 443 shares of Intuitive Surgical common stock and held no remaining derivative securities from the reported option grant. The filing notes that the transactions were made under a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027.
Intuitive Surgical (ISRG) executive Henry L. Charlton reported option exercises and open‑market sales on 11/12/2025 under a Rule 10b5‑1 trading plan. He exercised options for 636, 2,565, 2,898, and 2,901 shares at exercise prices of $347.4167, $245.6, $242.3367, and $177.9867, respectively, and reported multiple sales at $580 per share. Following the transactions, he directly owns 3,056 shares. The plan is stated to expire on June 1, 2026.
Intuitive Surgical (ISRG): Form 4 insider transaction. Director Craig H. Barratt exercised 750 stock options at $71.3233 and sold 750 common shares at $580 on 11/12/2025 under a Rule 10b5-1 trading plan.
Following these transactions, directly held common stock was 0. An additional 27,198 shares were reported as indirectly owned by a trust. The reported option was a non-qualified stock option; the derivative position shown was 0 after the exercise.
Intuitive Surgical (ISRG): Director transaction reported. Director Keith Leonard filed a Form 4 for a gift of 1,606 shares of common stock on 11/12/2025 (transaction code G) at a stated price of $0.0. The filing notes the shares were gifted to a CRUT.
Following the transaction, the reporting person’s beneficial ownership stands at 739 shares, held directly. This is a personal, non-cash transfer and does not reflect a sale in the market.